X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Elicio intends to use the net proceeds for the advancement of its development pipeline, including ELI-002, a lymph node–targeted mutant Kristen rat sarcoma (mKRAS) cancer vaccine, designed to target the most common KRAS mutations.
Lead Product(s): ELI-002
Therapeutic Area: Oncology Product Name: ELI-002
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 18, 2024
Details:
ELI-002 7P is an investigational therapeutic cancer vaccine developed with Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology. It is under phase 1/2 clinical development for the treatment of KRAS mutated pancreatic ductal adenocarcinoma.
Lead Product(s): ELI-002 7P
Therapeutic Area: Oncology Product Name: ELI-002 7P
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2024
Details:
Elicio intends to use the net proceeds for the advancement of its development pipeline, including ELI-002, an investigational therapeutic cancer vaccine created with its proprietary lymph node-targeting Amphiphile (AMP) technology.
Lead Product(s): ELI-002
Therapeutic Area: Oncology Product Name: ELI-002
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GKCC, LLC
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 22, 2023
Details:
The funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations.
Lead Product(s): ELI-007
Therapeutic Area: Oncology Product Name: ELI-007
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: GI Research Foundation
Deal Size: $5.4 million Upfront Cash: Undisclosed
Deal Type: Funding September 07, 2023
Details:
The combined company will focus on the advancement of its clinical development program, ELI-002, a therapeutic cancer vaccine designed with Elicio’s proprietary lymph node-targeting AMP technology, being evaluated in patients with mKRAS-driven solid tumors.
Lead Product(s): ELI-002
Therapeutic Area: Oncology Product Name: ELI-002 7P
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Recipient: Angion Biomedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger June 01, 2023
Details:
ELI-002 7P is an investigational therapeutic cancer vaccine, which targets seven mutations G12D, G12V, G12R, G12C, G12S, G12A and G13D in KRAS/NRAS mutated solid tumors.
Lead Product(s): ELI-002
Therapeutic Area: Oncology Product Name: ELI-002
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
The combined company will focus on advancing Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology to develop immunotherapies, with a focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.
Lead Product(s): ELI-002
Therapeutic Area: Oncology Product Name: ELI-002
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Angion Biomedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger January 17, 2023
Details:
ELI-005 (AMP-protein-based vaccines) administered intranasally to mice and nonhuman primates were transported across epithelial lining to nasal-associated lymphoid tissue (NALT) and persisted in nasal mucosa eliciting immune responses at both local and distal mucosal sites.
Lead Product(s): ELI-005
Therapeutic Area: Infections and Infectious Diseases Product Name: ELI-005
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
Funds will advance research into ELI-007 as a mutant BRAF-peptide vaccine and ELI-008 as a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations.
Lead Product(s): ELI-007
Therapeutic Area: Oncology Product Name: ELI-007
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Gastro-Intestinal Research Foundation
Deal Size: $2.8 million Upfront Cash: Undisclosed
Deal Type: Funding September 20, 2022
Details:
Data published in bioRxiv shows ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes in mice and non-human primates (NHPs).
Lead Product(s): ELI-005
Therapeutic Area: Infections and Infectious Diseases Product Name: ELI-005
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
